KRW 96700.0
(-6.84%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 98.61 Billion KRW | 37.15% |
2022 | 70.87 Billion KRW | 35.41% |
2021 | 52.33 Billion KRW | -19.72% |
2020 | 65.19 Billion KRW | 148.3% |
2019 | 26.25 Billion KRW | 13.71% |
2018 | 23.09 Billion KRW | 53.14% |
2017 | 15.07 Billion KRW | 17.3% |
2016 | 12.85 Billion KRW | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q2 | 36.48 Billion KRW | 55.84% |
2024 Q1 | 23.83 Billion KRW | -21.41% |
2023 Q1 | 21.06 Billion KRW | -31.9% |
2023 Q2 | 24.54 Billion KRW | 16.51% |
2023 Q3 | 21.27 Billion KRW | -13.33% |
2023 Q4 | 30.32 Billion KRW | 42.59% |
2023 FY | 97.19 Billion KRW | 37.15% |
2022 Q1 | 10.83 Billion KRW | -1.08% |
2022 FY | 70.87 Billion KRW | 35.41% |
2022 Q3 | 12.65 Billion KRW | -22.58% |
2022 Q2 | 16.34 Billion KRW | 50.84% |
2022 Q4 | 30.92 Billion KRW | 144.34% |
2021 FY | 52.33 Billion KRW | -19.72% |
2021 Q3 | 10.22 Billion KRW | 0.0% |
2021 Q4 | 10.95 Billion KRW | 7.18% |
2020 FY | 65.19 Billion KRW | 148.3% |
2019 FY | 26.25 Billion KRW | 13.71% |
2018 FY | 23.09 Billion KRW | 53.14% |
2017 FY | 15.07 Billion KRW | 17.3% |
2016 FY | 12.85 Billion KRW | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
HLB Co., Ltd. | 109.98 Billion KRW | 10.335% |
iNtRON Biotechnology, Inc. | 7.84 Billion KRW | -1156.968% |
BINEX Co., Ltd. | 55.67 Billion KRW | -77.132% |
Bioneer Corporation | 204.55 Billion KRW | 51.789% |
Anterogen.Co.,Ltd. | 7.74 Billion KRW | -1174.123% |
MEDIPOST Co., Ltd. | 65.31 Billion KRW | -50.991% |
CrystalGenomics, Inc. | 32.36 Billion KRW | -204.664% |
Helixmith Co., Ltd | 37.36 Billion KRW | -163.92% |
Chabiotech Co.,Ltd. | 285.93 Billion KRW | 65.51% |
Medy-Tox Inc. | 110.88 Billion KRW | 11.062% |
Peptron, Inc. | 16.65 Billion KRW | -492.076% |
Amicogen, Inc. | 52.82 Billion KRW | -86.697% |
Genexine, Inc. | 41.62 Billion KRW | -136.905% |
HLB Therapeutics Co.,Ltd. | 16.16 Billion KRW | -510.025% |
ALTEOGEN Inc. | 40.93 Billion KRW | -140.915% |
PharmaResearch Co., Ltd. | 89.44 Billion KRW | -10.262% |
SillaJen, Inc. | 5.11 Billion KRW | -1829.085% |
JETEMA, Co., Ltd. | 25.66 Billion KRW | -284.267% |
OliX Pharmaceuticals,Inc | 35.24 Billion KRW | -179.775% |
Genomictree Inc. | 16.26 Billion KRW | -506.334% |
MedPacto, Inc. | 26.91 Billion KRW | -266.351% |
D&D Pharmatech | 32.16 Billion KRW | -206.622% |
EASY BIO,Inc. | 29.67 Billion KRW | -232.366% |
GI Innovation, Inc. | 57.59 Billion KRW | -71.235% |